Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients (NCT06572553) | Clinical Trial Compass
UnknownPhase 2/3
Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients
China30 participantsStarted 2024-03-01
Plain-language summary
The goal of this clinical trial is to learn if drug Faricimab works to treat nAMD, DME or RVO in adults. It will also learn about the safety of drug Faricimab. The main questions it aims to answer are:
Does drug Faricimab can improve the best-corrected visual acuity of participants? What medical problems do participants have when inject drug Faricimab? Participants will inject drug Faricimab every month for 3 months. Visit the clinic once every 2 weeks for checkups.
Who can participate
Age range
50 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Chinese patients aged 18 years or older and of any gender;
. Patients who have been diagnosed with nAMD, DME or RVO by OCT, FFA, ICGA or OCTA;
. Patients whose decision to receive treatment with faricimab was made prior to and independent of study participation;
. Patients who have received at least one treatment with faricimab during the course of the study;
. have signed an informed consent form.
Exclusion criteria
. Active ocular inflammation or suspected active ocular infection in either eye;
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Best Corrected Visual Acuity (BCVA)
Timeframe: through study completion, an average of 3 months.
Trial details
NCT IDNCT06572553
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
. Receipt of any other anti-VEGF therapy after faricimab;
. Patient is unable to provide clinical data (visual acuity and OCT images) within 2 weeks (14 days) prior to receiving the initial faricimab injection;
. Currently participating in any other clinical trial.